One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Quidel Corporation logo
Quidel Corporation QDEL
$ 12.91 0.29%

Quidel Corporation Income Statement 2020-2011 | QDEL

Brief overview of revenue and earnings at Quidel Corporation

This overview is based on financial performance over the past five years. Revenue reported by Quidel Corporation was $196 million at the beginning of the period and $1.7 billion at the end. The five-year change reached +747.2%, while CAGR stood at 53.3%. The annual growth rate indicates an exceptionally strong top-line trend.

Gross profit was 124 million dollars at the start and 1.3 billion dollars at the end of the period (+983.9%). At the margin level, the figure shifted from 63.4% to 81.2%. The margin shift points to a more favorable sales-and-cost structure.

The five-year EBITDA result moved by +9500.7%: from $11.6 million to $1.1 billion. EBITDA grew faster than revenue, indicating positive operating leverage. EBITDA margin was 5.9% at the start and 67% at the end. A wider margin confirms stronger operating efficiency.

Comparing the endpoints shows a move from −6.1 million dollars to 810 million dollars. The return to profit marks a meaningful recovery in the final result.

Market value was 581 million dollars at the start and 10.6 billion dollars at the end. Capitalization grew more slowly than the underlying results.

Summary assessment

The financial trajectory looks strong and well balanced. Key strengths include a stronger gross margin, higher operating efficiency and a stronger final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Quidel Corporation

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

10.6 B 3.27 B 2.13 B 1.58 B 611 M 581 M 811 M 1.03 B 740 M 479 M

Shares

42.1 M 40.9 M 38 M 33.7 M 32.7 M 34.1 M 34.5 M 33.8 M 33.1 M 32.9 M

Net Income

810 M 72.9 M 74.2 M -8.16 M -13.8 M -6.08 M -7.07 M 7.39 M 4.99 M 7.63 M

Revenue

1.66 B 535 M 522 M 278 M 192 M 196 M 183 M 175 M 156 M 159 M

EBITDA

1.11 B 156 M 156 M 56.8 M 4.63 M 11.6 M 3.18 M 14.2 M 15.8 M 20.9 M

Operating Expenses

285 M 216 M 206 M 130 M 123 M 122 M 114 M 102 M 85.6 M 82 M

General and Administrative Expenses

66.6 M 164 M 154 M 96.4 M 74.9 M 77.3 M 67.3 M 60.1 M 51 M 48.5 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Quidel Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.74 0.98 % $ 24.4 B niderlandNiderland
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 11.44 2.69 % $ 389 M israelIsrael
Precipio Precipio
PRPO
$ 21.38 1.3 % $ 34.3 M usaUSA
RadNet RadNet
RDNT
$ 68.8 1.81 % $ 5.17 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 31.96 2.08 % $ 926 M usaUSA
Guardant Health Guardant Health
GH
$ 158.6 1.77 % $ 19.9 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 7.77 1.6 % $ 324 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 4.82 0.97 % $ 19.2 M israelIsrael
DexCom DexCom
DXCM
$ 86.04 0.07 % $ 33.6 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 266.9 0.11 % $ 45.9 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.18 5.31 % $ 22.6 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 436.95 0.65 % $ 26 B usaUSA
Exagen Exagen
XGN
$ 7.72 1.66 % $ 166 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.25 0.36 % $ 6.81 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.18 3.65 % $ 13.3 B irlandaIrlanda
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.85 6.81 % $ 3.82 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.53 0.62 % $ 1.15 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 690.0 3.46 % $ 260 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 132.75 0.45 % $ 7.94 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 17.89 0.03 % $ 5.08 B usaUSA
Natera Natera
NTRA
$ 393.44 2.54 % $ 53.8 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 46.13 0.15 % $ 10 B niderlandNiderland
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 8.03 1.26 % $ 2.88 B irlandaIrlanda
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.0 0.36 % $ 26.1 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 560.36 2.41 % $ 45.1 B usaUSA
Personalis Personalis
PSNL
$ 15.65 0.19 % $ 1.4 B usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 6.47 2.11 % $ 28.6 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 1.85 3.0 % $ 5.39 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.98 4.82 % $ 369 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.73 0.73 % $ 519 M usaUSA
Neuronetics Neuronetics
STIM
$ 1.89 3.45 % $ 125 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 172.97 0.07 % $ 49.1 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 300.15 0.79 % $ 14.9 B usaUSA